Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06672185 · ClinicalTrials.gov registry record · Phase 1
ARC101 in Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Third Arc Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 10
- Study locations
NCT06672185: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Third Arc Bio.
NCT06672185 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Third Arc Bio. The registered enrollment target is 70 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (64% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06672185, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Third Arc Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 10
- Study locations
Study Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.
Conditions Studied
Interventions
- DRUG ARC101
Study Locations (10)
Other
- Rambam Medical Center - Haifa
- Sheba Medical Center - Ramat Gan
- Sourasky Medical Center - Tel Aviv
Michigan
- START Midwest - Grand Rapids
Texas
- START San Antonio, LLC. - San Antonio
Queensland
- Sunshine Coast University Private Hospital - Birtinya
South Australia
- Cancer Research SA - Adelaide
Victoria
- Cabrini Health Research - Malvern
British Columbia
- BC Cancer Research Centre - Vancouver
Ontario
- The Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-02-05 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 1 |
What NCT06672185 shows while recruiting
NCT06672185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ARC101 is the first listed.
NCT06672185 lists 10 locations in 8 states (Other, Michigan, Texas).
Frequently Asked Questions
What is clinical trial NCT06672185 about?
NCT06672185 is a clinical study titled "ARC101 in Advanced Solid Tumors". This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.
What is the current status of trial NCT06672185?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2025-02-05. Estimated completion is 2028-08-01.
What conditions does trial NCT06672185 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06672185?
The interventions under investigation include: ARC101 (DRUG).
Who is sponsoring clinical trial NCT06672185?
This trial is sponsored by Third Arc Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06672185 being conducted?
This trial has 10 study locations across Michigan, Texas, Queensland, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06672185's enrollment target sits among peer trials
70 142nd of 189 higher than 42 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI